Shanxi Medical University Anisomycin Derivative Patent for Diabetes as GLP-1R Agonist
Summary
The USPTO granted patent US12612362B2 to Shanxi Medical University on April 28, 2026, covering an anisomycin derivative represented by general formula (I) as a GLP-1R agonist. The invention was found to promote insulin secretion under high blood sugar concentrations and can treat diabetes while preventing hypoglycemia. The patent also covers use for treating GLP-1R-mediated diseases including obesity. The application was filed on July 24, 2023, with 5 claims granted.
“The present invention relates to an anisomycin derivative represented by general formula (I) or pharmaceutically acceptable salts, solvates and stereoisomers thereof.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO issued patent US12612362B2 to Shanxi Medical University covering an anisomycin derivative and its use as a small molecule GLP-1R agonist. The patent claims the compound and its pharmaceutical applications for treating diabetes, preventing hypoglycemia, and addressing other GLP-1R-mediated diseases including obesity. The filing date was July 24, 2023, with 5 claims granted.
For pharmaceutical companies engaged in GLP-1 receptor agonist research or diabetes drug development, this patent represents potential licensing opportunities or considerations for design-around strategies. Patent holders and researchers in metabolic disease therapeutics should review the granted claims to assess freedom-to-operate implications for their own programs.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anisomycin derivative and use of anisomycin and derivative thereof as GLP-1R agonist
Grant US12612362B2 Kind: B2 Apr 28, 2026
Assignee
SHANXI MEDICAL UNIVERSITY
Inventors
Yi Zhang, Huan Xue, Min Zhang, ZhiHong Lu, Linping Zhi, Zhitong Wen, Lijuan Cui, Tao Bai, Yunfeng Liu
Abstract
The present invention relates to an anisomycin derivative represented by general formula (I) or pharmaceutically acceptable salts, solvates and stereoisomers thereof. According to the present invention, it is found that anisomycin and derivatives thereof have the effect of promoting insulin secretion under high blood sugar concentrations, and can treat diabetes and prevent the occurrence of hypoglycemia. It is found, by studying its mechanism of action, that the anisomycin derivative is highly related to GLP-1R, indicating that the anisomycin derivative is a small molecule GLP-1R agonist, which can effectively treat a variety of GLP-1R-mediated diseases including obesity and diabetes, and has good commercial application prospects and scientific research value.
CPC Classifications
C07D 207/46 A61P 3/10
Filing Date
2023-07-24
Application No.
18357985
Claims
5
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.